These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19255335)

  • 1. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
    Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
    J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
    Couto Mdo R; Pinto D; Oliveira J; Monteiro A; Pereira D; Medeiros R; Rodrigues H
    Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
    Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
    Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
    Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
    Witzel I; Loibl S; von Minckwitz G; Mundhenke C; Huober J; Hanusch C; Henschen S; Hauschild M; Lantzsch T; Tesch H; Latos K; Just M; Hilfrich J; Barinoff J; Eulenburg CZ; Roller M; Untch M; Müller V
    Breast Cancer Res Treat; 2010 Sep; 123(2):437-45. PubMed ID: 20623180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
    Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
    Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
    Ghedini GC; Ciravolo V; Tortoreto M; Giuffrè S; Bianchi F; Campiglio M; Mortarino M; Figini M; Coliva A; Carcangiu ML; Zambetti M; Piazza T; Ferrini S; Ménard S; Tagliabue E; Pupa SM
    J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer.
    Sorensen BS; Mortensen LS; Andersen J; Nexo E
    Anticancer Res; 2010 Jun; 30(6):2463-8. PubMed ID: 20651409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
    Lipton A; Leitzel K; Ali SM; Carney W; Platek G; Steplewski K; Westlund R; Gagnon R; Martin AM; Maltzman J
    Cancer; 2011 Nov; 117(21):5013-20. PubMed ID: 21456017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.